Neurofibroma, Plexiform clinical trials
The registry lists 66 studies for Neurofibroma, Plexiform across more than 10 countries. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-24.
Status
- Completed
- 23
- Active, not recruiting
- 14
- Recruiting
- 13
- Terminated
- 7
- Withdrawn
- 3
- Enrolling by invitation
- 2
Phase
- Phase 2
- 28
- Phase 1
- 15
- Phase 3
- 4
- Phase 4
- 1
- Early Phase 1
- 1
Where
- United States
- 48
- China
- 10
- France
- 5
- Canada
- 5
- United Kingdom
- 4
- Australia
- 4
Who runs them
National Cancer Institute (NCI) (18) · AstraZeneca (7) · Indiana University (4) · Novartis Pharmaceuticals (3) · University of Alabama at Birmingham (3) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (3) · Children's Hospital of Philadelphia (3) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 66 — search for more.
- Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)RecruitingNCT025440221 country
- Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1Enrolling by invitationNCT052389091 country
- Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)RecruitingNCT062222031 country
- Neurofibromatosis Type 1 Tumor Early Detection StudyEnrolling by invitationNCT065158601 country
- Real-World Treatment Study of Koselugo (Selumetinib)RecruitingNCT063604061 country
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingNCT02390752Phase 11 country
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingNCT06502171Phase 11 country
- A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1RecruitingNCT06541847Phase 21 country
- A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)RecruitingNCT06507748Not applicable1 country
- Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1RecruitingNCT06188741Phase 21 country
- Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform NeurofibromasRecruitingNCT07407803Phase 31 country
- Individual Patient Compassionate Use of MirdametinibAvailableNCT05028166
- PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasRecruitingNCT06961565Phase 13 countries
- Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1Not yet recruitingNCT07024394Phase 1/21 country
- Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese ChildrenNot yet recruitingNCT06763315Phase 21 country
- A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)RecruitingNCT063792301 country
- Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1RecruitingNCT05199376Not applicable1 country
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasRecruitingNCT05331105Phase 21 country
- Natural History Study of Patients With Neurofibromatosis Type IActive, not recruitingNCT009241961 country
- Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNsActive, not recruitingNCT061756371 country
- AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsActive, not recruitingNCT01362803Phase 1/21 country
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasActive, not recruitingNCT02407405Phase 21 country
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruitingNCT03975829Phase 419 countries
- A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)Active, not recruitingNCT04590235Phase 11 country
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive, not recruitingNCT03962543Phase 21 country
- A Study of Avutometinib for People With Solid Tumor CancersActive, not recruitingNCT06104488Phase 11 country
- Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.Active, not recruitingNCT03363217Phase 21 country
- Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasActive, not recruitingNCT04924608Phase 313 countries
- Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.CompletedNCT027777751 country
- US Selumetinib RegistryTerminatedNCT056836781 country
- FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasActive, not recruitingNCT05913037Phase 31 country
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1Active, not recruitingNCT04954001Phase 1/23 countries
- Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)CompletedNCT047742891 country
- Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment TrialsCompletedNCT03531814Not applicable1 country
- Treatment of NF1-related Plexiform Neurofibroma With TrametinibActive, not recruitingNCT03741101Phase 21 country
- Intermittent Dosing Of Selumetinib In Childhood NF1 Associated TumoursCompletedNCT03326388Phase 1/21 country
- Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical TrialCompletedNCT048791601 country
- Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled StudyWithdrawnNCT05825365Phase 2
- Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and AdultsCompletedNCT02101736Phase 21 country
- Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic PainCompletedNCT02471339Phase 31 country
- Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 MutationsCompletedNCT02124772Phase 1/25 countries
- PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)CompletedNCT018000321 country
- Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1Active, not recruitingNCT03820778Not applicable1 country
- Study of Imatinib in Children With Neurofibromatosis and Airway TumorsWithdrawnNCT03688568Phase 21 country
- Clinical Sequencing of Cancer and Tissue Repository: OncoGenomicsWithdrawnNCT030274011 country
- Study of Plexiform Neurofibromas in Neurofibromatosis Type 1CompletedNCT000064351 country
- An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1Approved for marketingNCT032596331 country
- Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug DevelopmentCompletedNCT003405221 country
- Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasTerminatedNCT02177825Phase 21 country
- A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male ParticipantsCompletedNCT03649165Phase 11 country